
Opinion|Videos|May 2, 2025
Balancing Survival and Quality of Life in 1L EGFRm NSCLC Treatment Decisions
Panelists discuss how treatment choice involves weighing quality of life against treatment burden, considering factors such as hospital visits for infusions vs oral medications at home.
Advertisement
Episodes in this series

Quality of Life vs Treatment Burden
Main Discussion Topics:
- Impact of different treatment regimens on patient quality of life
- Comparison of treatment burdens: oral therapy vs infusion-based regimens
- Consideration of financial costs and logistical challenges associated with different treatments
Key Points for Physicians:
- Treatment burden varies significantly: osimertinib is a daily pill with visits every 3 months, whereas combination therapies require infusions every 2 to 3 weeks
- More-intensive regimens involve greater “medicalization” of patient care
- Financial and logistical costs (travel, parking, childcare) must be considered
Notable Insights:
Patients fall on different ends of the spectrum regarding treatment preferences—some prioritize efficacy regardless of burden, and others prefer less- intensive regimens to maintain quality of life.
Clinical Significance:
The treatment decision ultimately depends on aligning therapy choice with individual patient values, circumstances, and priorities related to efficacy, quality of life, and treatment burden.
Advertisement
Related to this article

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.

Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.

A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.

The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
4
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
5

